Bristol-Myers: Analysts' Upgrades, Downgrades

NEW YORK (TheStreet) -- CHANGE IN RATINGS

Amylin Pharmaceuticals ( AMLM) initiated at Credit Suisse with an Outperform rating and $28 price target. Analysts noted improved confidence in Byetta and potential acquisition interest. 2010 and 2011 EPS estimates set at -$0.75 and -$0.10, respectively.

AOL ( AOL) rated new Hold at Jefferies.$27 price target. Company is re-inventing itself, but lacks near-term catalysts.

Dell ( DELL) upgraded at UBS from Neutral to Buy. $16 price target. Valuation call, as gross margins have bottomed.

Kimberly-Clark ( KMB) downgraded at Goldman from Neutral to Sell. Estimates also lowered, because of higher expected pulp prices. New $60 price target.

Micron Technology ( MU) downgraded at UBS from Buy to Neutral. $10.50 price target. Estimates also lowered, because of market oversupply.

MSCI ( MXB) upgraded at UBS from Neutral to Buy. Stock has fallen 14% since mid-December, though the RiskMetrics acquisition should add to earnings. $40 price target.

OSI Pharmaceuticals ( OSIP) downgraded at UBS from Buy to Neutral. $56 price target. Roche bid is unlikely, but the stock is already pricing in the majority of the takeover premium.

OSI Pharmaceuticals ( OSIP) target upped at Goldman to $48. Hostile bid has helped boost the value. Neutral rating.

Rowan ( RDC) downgraded at MKM from Buy to Neutral. Valuation call, as the stock is up 21% since late January.

Shanda Interactive ( SNDA) downgraded at Roth from Buy to Hold. $48 price target. Company has limited earnings visibility, following the recent profit miss.

Sandisk ( SNDK) upgraded at UBS from Sell to Neutral. $34 price target. Estimates also raised, as pricing should improve along with handset storage growth.

Southern Union ( SUG) downgraded at Stifel from Buy to Hold. Stock is already pricing in strength in the Gathering and Processing segment.

Westar Energy ( WR) upgraded at Wells to Outperform. Estimates also raised, because of expected base rate relief.

Exco Resources ( XCO) initiated at Barclays with an Overweight rating and $29 price target. 2010 could mark the beginning of an aggressive growth profile driven by the Haynesville and Marcellus shale plays.

STOCK COMMENTS / EPS CHANGES

Boeing ( BA) 2011 EPS estimates introduced at $5.10, 2010 maintained at $4.40. Reiterate Overweight rating and $65 target.

BE Aerospace ( BEAV) estimates upped at UBS through 2011. Company said at its investor day that consumables orders are picking up. Neutral rating and $24 price target.

Bristol-Myers ( BMY) estimates reduced at Goldman through 2012. Company is seeing lower belatacept sale and not paying down as much debt. Neutral rating and $26 price target.

Cliffs Natural ( CLF) estimates boosted at Morgan Stanley through 2011. Company should benefit from better steel raw material pricing. Equal-weight rating.

Dish Network ( DISH) numbers boosted at Goldman. Estimates were increased through 2012. Company is seeing more new subscribers and better cost controls. Sell rating and new $18 price target.

El Paso ( EP) estimates, target increased at Goldman. Shares of EP now seen reaching $12. Estimates also raised, as the company is seeing higher margins. Neutral rating.

Interpid Potash ( IPI) estimates reduced at UBS through 2011. Company is seeing softer pricing. Neutral rating and $30 price target.

Mylan ( MYL) target, estimates boosted at Barclays. MYL price target jumped to $25 from $20 on valuation and earnings potential. 2010 EPS estimate increased to $1.57, 2011 introduced at $2.01. Maintain Overweight rating.

Nuvasive ( NUVA) estimates, target increased at Goldman. NUVA estimates were boosted through 2012. New insurance coverage is a positive surprise. Neutral rating and new $44 price target.

PHH ( PHH) estimates, target raised at FBR. Shares of PHH now seen reaching $25. Estimates also increased, given the company's strong earnings momentum. Outperform rating.

Smithfield Foods ( SFD) estimates raised at Morgan Stanley through 2011. Company is seeing lower costs and higher lean hog prices. Equal-weight rating.

Venoco ( VQ) price target tweaked at Credit Suisse. VQ price target raised by a dollar to $13. 2010 and 2011 EPS estimates lowered to 40 cents and 72 cents, respectively. Maintain Neutral rating.

Verizon ( VZ) 2011 EPS estimates introduced at $2.49, 2010 maintained at $2.05. Reiterate Equal Weight rating and $33 price target.

Warner Chilcott ( WCRX) estimates increased at UBS. WCRX estimates were raised through 2011. Company is seeing higher sales. Buy rating and $33 price target.

This article was written by a staff member of TheStreet.com.

More from Stocks

Markets Look Confused After Latest Beating

Markets Look Confused After Latest Beating

General Electric Expulsion From Dow Symbolizes Unsettled Week in Markets

General Electric Expulsion From Dow Symbolizes Unsettled Week in Markets

How Small-Cap Stocks Can Protect Your Portfolio From a Trade War

How Small-Cap Stocks Can Protect Your Portfolio From a Trade War

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

3 Great Stock Market Sectors Millennials Should Invest In

3 Great Stock Market Sectors Millennials Should Invest In